170 related articles for article (PubMed ID: 38443927)
21. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8
Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ
J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450
[TBL] [Abstract][Full Text] [Related]
22. Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2.
Li G; Xiong Z; Li Y; Yan C; Cheng Y; Wang Y; Li J; Dai Z; Zhang D; Du W; Men C; Shi C
Discov Oncol; 2024 Apr; 15(1):110. PubMed ID: 38598023
[TBL] [Abstract][Full Text] [Related]
23. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
24. ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.
Yan T; Hu P; Lv S; Ye M; Wu M; Fang H; Xiao B
Cancer Chemother Pharmacol; 2024 Jun; ():. PubMed ID: 38824270
[TBL] [Abstract][Full Text] [Related]
25. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Ding C; Yi X; Wu X; Bu X; Wang D; Wu Z; Zhang G; Gu J; Kang D
Cancer Lett; 2020 Jun; 479():1-12. PubMed ID: 32194140
[TBL] [Abstract][Full Text] [Related]
26. Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Fei YQ; Shi RT; Zhou YF; Wu JZ; Song Z
Neurochem Int; 2022 Jul; 157():105348. PubMed ID: 35490896
[TBL] [Abstract][Full Text] [Related]
27. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
28. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
29. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Wei Y; Duan S; Gong F; Li Q
Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
[TBL] [Abstract][Full Text] [Related]
30. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
[TBL] [Abstract][Full Text] [Related]
31. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
32. Integrin α
Huang CW; Chuang CP; Chen YJ; Wang HY; Lin JJ; Huang CY; Wei KC; Huang FT
J Nanobiotechnology; 2021 Jun; 19(1):180. PubMed ID: 34120610
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
34. Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Szymczak B; Czarnecka J; Czach S; Nowak W; Roszek K
Cell Signal; 2023 Jun; 106():110641. PubMed ID: 36858191
[TBL] [Abstract][Full Text] [Related]
35. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
36. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
37. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
38. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
40. Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Zhao Z; Shen J; Zhang L; Wang L; Xu H; Han Y; Jia J; Lu Y; Yu R; Liu H
Biomater Sci; 2020 Sep; 8(19):5306-5316. PubMed ID: 32573615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
